A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The primary purpose of participation in this study is to compare the safety and efficacy of
different dosing schedules of LY2605541 and how different dosing schedules of LY2605541
affect Hemoglobin A1c (HbA1c). Participants will be treated for up to 36 weeks with LY2605541
(one 12-week Lead-in period and two 12-week Randomization periods) and will participate in a
total of 42 weeks of total study enrollment, including a 2-week Screening period and a 4-week
Follow-up period.